News
The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...
Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback